RARE Ultragenyx Pharmaceutical
- 42.750
- -0.450-1.04%
- 43.580
- +0.830+1.94%
Ultragenyx Pharmaceutical News
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target
Ultragenyx Pharmaceutical Analyst Ratings
Truist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)
Ultragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potential
Ultragenyx Pharmaceutical Analyst Ratings
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical (RARE.US) was first covered by the Royal Bank of Canada, which gave it an superior market rating and a target price of $77.00.
Ultragenyx Pharmaceutical Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
Buy Rating on Ultragenyx Pharmaceutical Bolstered by GTX-102's Promise and Positive Valuation Outlook
Wedbush: Reiterates Ultragenyx Pharmaceutical's (RARE.US) rating, adjusted from neutral to neutral, with a target price of $48.00.
Ultragenyx Pharmaceutical Analyst Ratings
Wedbush: Reiterates Ultragenyx Pharmaceutical's (RARE.US) rating, adjusted from neutral to neutral, with a target price of $48.00.
Ultragenyx Pharmaceutical Analyst Ratings
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)
Analysts' Top Healthcare Picks: Neurocrine (NBIX), Ultragenyx Pharmaceutical (RARE)
Analysis
Price Target
No Data
